120 related articles for article (PubMed ID: 12895265)
1. High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial.
Boucher EJ; Jacquelinet S; Canva V; Turlin B; Jacquelinet C; Colimon R; Deugnier Y; Guyader D; Brissot P
Liver Int; 2003 Aug; 23(4):255-61. PubMed ID: 12895265
[TBL] [Abstract][Full Text] [Related]
2. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
[TBL] [Abstract][Full Text] [Related]
3. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
[TBL] [Abstract][Full Text] [Related]
4. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Steindl-Munda P; Ferenci P; Brunner H; Nachbaur K; Datz C; Gschwantler M; Hofer H; Stauber R; Hackl F; Jessner W; Rosenbeiger M; Gangl A; Vogel W;
Liver Int; 2003 Aug; 23(4):269-75. PubMed ID: 12895267
[TBL] [Abstract][Full Text] [Related]
5. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
Portal I; Bourlière M; Halfon P; De Lédinghen V; Couzigou P; Bernard PH; Blanc F; Caroli-Bosc F; Arpurt JP; Vetter D; Mathieu-Chandelier C; Chazouillères O; Thiefin G; Pol S; Sogni P; Abergel A; Bailly F; Picon M; Debonne JM; Zamora C; Alleman I; Moreau X; Doll F; Eugène C; Ducloux S; Larrey D; Ouzan D; Grimaud JC; Gouvernet J; Botti G; Gérolami V; Khiri H; Gérolami A; Gauthier AP; Botta-Fridlund D
J Viral Hepat; 2003 May; 10(3):215-23. PubMed ID: 12753341
[TBL] [Abstract][Full Text] [Related]
6. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
[TBL] [Abstract][Full Text] [Related]
7. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
8. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
9. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
Buti M; Olive G; Stalgis C; Esteban R; Guardi J
Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
[TBL] [Abstract][Full Text] [Related]
10. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
Barbaro G; Barbarini G
Eur J Gastroenterol Hepatol; 2002 May; 14(5):477-83. PubMed ID: 11984144
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
[TBL] [Abstract][Full Text] [Related]
12. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
13. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
Barbaro G; Di Lorenzo G; Belloni G; Ferrari L; Paiano A; Del Poggio P; Bacca D; Fruttaldo L; Mongiò F; Francavilla R; Scotto G; Grisorio B; Calleri G; Annese M; Barelli A; Rocchetto P; Rizzo G; Gualandi G; Poltronieri I; Barbarini G
Am J Med; 1999 Aug; 107(2):112-8. PubMed ID: 10460040
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
[TBL] [Abstract][Full Text] [Related]
15. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
August-Jörg BS; Borovicka J; Dufour JF; Gonvers JJ; Henz S; Hermann R; Meyenberger C; Weitz M; Renner EL;
Swiss Med Wkly; 2003 Aug; 133(33-34):455-60. PubMed ID: 14625812
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
[TBL] [Abstract][Full Text] [Related]
17. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
Weegink CJ; Sentjens RE; Beld MG; Dijkgraaf MG; Reesink HW
J Viral Hepat; 2003 May; 10(3):174-82. PubMed ID: 12753335
[TBL] [Abstract][Full Text] [Related]
18. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
Moucari R; Ripault MP; Oulès V; Martinot-Peignoux M; Asselah T; Boyer N; El Ray A; Cazals-Hatem D; Vidaud D; Valla D; Bourlière M; Marcellin P
J Hepatol; 2007 Apr; 46(4):596-604. PubMed ID: 17218037
[TBL] [Abstract][Full Text] [Related]
19. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
Fattovich G; Zagni I; Fornaciari G; Minola E; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Montanari R; Paternoster C; Distasi M; Castagnetti E; Tositti G; Rizzo C; Suppressa S; Pantalena M; Lomonaco L; Scattolini C; Tagger A
J Viral Hepat; 2003 Mar; 10(2):111-7. PubMed ID: 12614467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
